SAN DIEGO--(BUSINESS WIRE)--Orexigen™ Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders including obesity, today announced the initiation of the third trial in its Phase III clinical trial program for its lead product candidate Contrave™ as a treatment for obesity. The program includes a set of four Phase III trials evaluating a variety of obesity-related outcome measures.
This clinical trial is a 58-week study designed to assess the safety, tolerability and efficacy of Contrave in healthy, nondiabetic, obese patients. The trial is designed to take place at approximately 40 centers nationwide and Orexigen plans to enroll approximately 1650 patients.
